Cargando…
Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
Benefits and risks of SGLT2 inhibitor use.[Image: see text]
Autores principales: | Fujita, Yoshihito, Inagaki, Nobuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825932/ https://www.ncbi.nlm.nih.gov/pubmed/31541588 http://dx.doi.org/10.1111/jdi.13150 |
Ejemplares similares
-
Impaired insulin secretion and related factors in East Asian individuals
por: Nakamura, Akinobu, et al.
Publicado: (2021) -
Advancements in transplantation therapy for diabetes: Pancreas, islet and stem cell
por: Nakamura, Toshihiro, et al.
Publicado: (2020) -
Blood glucose control: Where are we?
por: Lee, Moon‐Kyu
Publicado: (2021) -
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
por: Lin, Kuan‐Yu, et al.
Publicado: (2021) -
Updates in diabetic neuropathy: A call for new diagnostic and treatment approaches
por: Aso, Yoshimasa
Publicado: (2021)